Rhythm expands LG Chem bivamelagon obesity licence to $855 million and revises royalties

Rhythm Pharmaceuticals has substantially expanded its existing bivamelagon licensing agreement with LG Chem, increasing potential deal consideration to $855 million while securing revised royalty economics across specified MC4R therapies.
The amendment announced on 2 November 2026 adds $350 million in fixed payments over four years and a potential $200 million milestone linked to $3 billion in annual global MC4R portfolio sales, raising the agreement's stated potential value from $305 million to $855 million.
In exchange, LG Chem's royalties change from low-to-mid-single-digit rates to 1% of global net sales across specified Rhythm MC4R agonists, while Rhythm's separately arranged term-loan facility of up to $750 million represents financing rather than consideration paid under the licence.
Field | Content |
Article Type | Deals |
Company | Rhythm Pharmaceuticals |
Licensing Partner | LG Chem |
Deal Type | Material amendment to existing exclusive licence agreement |
Amendment Announcement Date | 2 November 2026 |
Licensed Asset | Bivamelagon |
Drug Class | Melanocortin-4 receptor agonist |
Target | MC4R |
Modality | Oral small-molecule therapeutic |
Administration Route | Oral |
Therapeutic Area | Rare obesity disorders |
Development Status | Investigational |
Original Potential Agreement Value | $305 million |
Revised Potential Agreement Value | $855 million |
Additional Fixed Payments | $350 million over four years |
Additional Contingent Milestone | Up to $200 million |
Milestone Trigger | $3 billion in annual global MC4R portfolio sales |
Previous Royalty Structure | Low-to-mid-single-digit royalties |
Revised Royalty Structure | 1% of global net sales across specified Rhythm MC4R agonists |
Royalty Scope | Specified MC4R agonists within Rhythm's portfolio |
Separate Financing Arrangement | Term-loan facility providing access to up to $750 million |
Financing Clarification | The term-loan facility is separate financing and is not licence consideration |
Geographic Scope | Global sales referenced in the amended royalty and milestone terms |
What Happened | Rhythm and LG Chem amended their existing bivamelagon licence to increase fixed and contingent payments while reducing specified royalty obligations. |
Why It Matters | The amendment materially changes the economics of Rhythm's rare obesity portfolio by exchanging increased payment commitments for lower ongoing royalties. |
Strategic Rationale | Improve long-term royalty economics across specified MC4R therapies while maintaining development rights to bivamelagon. |
Financial Clarification | The $855 million represents the amended agreement's stated potential value, including contingent consideration, rather than an upfront payment. |
Transaction Distinction | Amendment to an existing licence; not a newly acquired asset or regulatory approval. |
Key Takeaway | Rhythm committed to additional fixed payments and a potential sales milestone in return for a revised 1% royalty structure. |
What to Watch | Bivamelagon clinical development, MC4R portfolio sales, fixed payment schedules, milestone triggers and future financing needs. |
Primary Source | Rhythm Pharmaceuticals |
Primary Source URL | https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-and-lg-chem-enter-amendment-bivamelagon |
Relevant Date | 2 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Kommentare